Addressing Challenges and Opportunities in Treating Duchenne Muscular Dystrophy

Video

The co-founder, president, and chief executive officer of Solid Biosciences, whose own son has DMD, discussed promising updates from their phase 1/2 IGNITE-DMD trial.

"Duchenne muscular dystrophy is a really challenging disease to measure in the clinic. It's easy to measure the biomarker; it's more difficult to correlate that with outcomes. But from what we have seen, which is just very few patients at around a 1-year time point, we are certainly encouraged and excited that we have a treatment that may well be improving outcomes.”

Finding an effective, targeted treatment for Duchenne muscular dystrophy (DMD) is personal for Solid Biosciences co-founder Ilan Ganot, whose son has been diagnosed with the disease. The company, for which Ganot also serves as president and chief executive officer, is harnessing advanced gene therapy approaches to try and fill a great unmet need for patients with the neuromuscular disease.

Solid considers their approach to research and development “technology agnostic,” in that they are more focused on the treatment strategies that will solve the most problems for patients versus those that can be addressed by a single approach. Their lead program, a gene therapy transfer agent, is currently in phase 1/2 clinical trials.

SGT-001 has continued to show safety and efficacy in the first 8 patients dosed. Data from the first 6 patients showed that those who received a high-dose version exhibited 5% to 17.5% of normal microdystrophin expression levels by Western blot and 20% to 70% of positive muscle fibers by immunofluorescence.

In an interview with GeneTherapyLive, Ganot shared more about the company’s motivations and how Solid is persevering in DMD despite inherent clinical challenges.  

REFERENCE
Morris CA, Clary CM, Redican S, et al. IGNITE-DMD phase I/II study of SGT-001 microdystrophin gene therapy for Duchenne muscular dystrophy. Presented at: 2021 American Society of Gene & Cell Therapy Annual Meeting; May 12-15, 2021. Abstract 263
Related Videos
Xandra Breakefield, PhD, on Trying New Approaches to AAV Therapy for Glioblastoma
Nathan Yozwiak, PhD, on Researching AAV Gene Therapy Delivery to the Brain
Salvador Rico, MD, PhD, on Informing Clinical Trials With Natural History Studies in Dravet
Zheng-Yi Chen, DPhil, on International Collaboration on Clinical Trials
Janice Chen, PhD, the cofounder and chief technology officer of Mammoth Biosciences
Sekar Kethiresan, MD, on Following up VERVE-101 With Next-Generation Editing Therapies
Maria Escolar, MD, the chief medical officer of Forge Biologics
Leigh Ramos-Platt, MD, on Allowing Access and Ensuring Preparation for Gene Therapies
John Murphy, PhD, the chief scientific officer of Arbor Biotechnologies
Erika Fullwood Augustine, MD, MS, the associate chief science officer of the Kennedy Krieger Institute
© 2024 MJH Life Sciences

All rights reserved.